Technology and managing risk within the high potency drug sector

19 Mar 2018

Manufacturing high potency drugs - the challenges and innovations to mitigate the risks.

The huge global demand within potent drug production - whether this be in the development of antibody drug conjugates (ADCs) or in the need for conventional drug manufacturing - is encouraging requests for high potency handling and, therefore, a need for high-containment facilities. Michael Avraam, global product manager at ChargePoint Technology for the PharmaSafe range of products, talks to CPhI Online about the risks, challenges and innovation in today's high potency drug sector.

Technology and managing risk within the high potency drug sector

How is demand for high potency manufacturing affecting the industry?

The increasing demand for the capability to handle high potency drugs is having a significant impact on the sector. Many existing manufacturing facilities, unfortunately, do not have these facilities and therefore companies are needing to upgrade, develop, and sometimes even construct new facilities to meet customer needs. These facilities have also had to be designed to be easily adaptable for the variation in production that high potency drugs can bring. This rising demand has also placed an importance on selecting the right outsourcing partners to offer these specialist capabilities, which is shaping the contract manufacturing landscape. If a prospective partner can demonstrate the ability to be flexible in the containment solutions they offer, particularly in their capacity to scale up production and be proactive, they will be more successful.

Where do the challenges lie in the manufacture of high potency drugs?

The most significant challenge will always lie in the handling of these ingredients across the supply chain. Not only regarding which equipment is needed to ensure product protection and avoidance of cross-contamination, but also in the importance of operator and environmental safety. Employees and their environment need to be shielded from exposure to these drugs and their safety rests on the manufacturer’s ability to select the correct containment solution to suit the process. How this solution is selected, installed and set-up is of vital importance as it will impact the overall safety. Appropriate and ongoing training is therefore essential, as well as the continuous monitoring of operations to guarantee maximum protection and that safety is always put first. Due to the complex nature of high potency drugs, finding a balance between ensuring safety whilst maintaining productivity and operability can present another challenge. This often requires upgrading or investing in new equipment which can be particularly challenging for smaller manufacturers.

In what other ways can risk be controlled when using high potency ingredients?

Technology plays a big role in minimising the risks associated with potent compounds. Some examples include rigid and flexible barrier isolators, which offer good levels of containment security. Extracted booth technology can also assist in handling larger operations as it can give a secondary level of containment protection. New design technologies also assist in removing the risk of airborne exposure, and have been the key to achieving high containment in recent years. Split butterfly valves (SBVs) have evolved over the last 25 years with the rise in high potency manufacturing and have presented a novel and versatile approach that can be easily integrated across containment solutions. The use of closed containment systems such as this minimise risk, without damaging productivity.

How is technology continuing to shape the high potency industry?

Ultimately, advancements in technology have driven the changes we are witnessing in manufacturing facilities, and they will continue to do so in the future. Technology aimed at reducing risk will continue to be the number one priority. The future presents opportunities such as using robotics to remove all physical human interaction with harmful substances. Industry 4.0 has already begun to take hold in the automation of systems across the board.

Read More

Related news

'Tamper-evident' benefits are evident

'Tamper-evident' benefits are evident

28 Feb 2019

2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

Read more 
All Recipharm facilities ready for EU serialisation, regardless of Brexit

All Recipharm facilities ready for EU serialisation, regardless of Brexit

15 Feb 2019

The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.

Read more 
Brexit - the EU FMD's painful problem

Brexit - the EU FMD's painful problem

7 Feb 2019

Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.

Read more 
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

27 Jan 2019

New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

Read more 
New API screening program strengthens Particle Sciences' nanomilling offering

New API screening program strengthens Particle Sciences' nanomilling offering

22 Jan 2019

Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.

Read more 
Univercells introduces breakthrough vaccine manufacturing platform

Univercells introduces breakthrough vaccine manufacturing platform

13 Jan 2019

The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more 
One month on: medical cannabis is still taboo despite change in law

One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more